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Abstract
Background: The prices of reverse transcriptase (RT) inhibitors in Thailand have been reduced
since December 1, 2001. It is expected that reduction in the price of these inhibitors may influence
the drug resistance mutation pattern of HIV-1 among infected people. This study reports the
frequency of HIV-1 genetic mutation associated with drug resistance in antiretroviral-treated
patients from Thailand.
Methods: Genotypic resistance testing was performed on samples collected in 2002 from 88 HIV-
1 infected individuals. Automated DNA sequencing was used to genotype the HIV-1 polymerase
gene isolated from patients' plasma.
Results: Resistance to protease inhibitors, nucleoside and non-nucleoside reverse transcriptase
inhibitors were found in 10 (12%), 42 (48%) and 19 (21%) patients, respectively. The most common
drug resistance mutations in the protease gene were at codon 82 (8%), 90 (7%) and 54 (6%),
whereas resistant mutations at codon 215 (45%), 67 (40%), 41 (38%) and 184 (27%) were
commonly found in the RT gene. This finding indicates that genotypic resistance to nucleoside
reverse transcriptase inhibitors was prevalent in 2002. The frequency of resistant mutations
corresponding to non-nucleoside reverse transcriptase inhibitors was three times higher-, while
resistant mutation corresponding to protease inhibitors was two times lower than those
frequencies determined in 2001.
Conclusion: This study shows that the frequencies of RT inhibitor resistance mutations have been
increased after the reduction in the price of RT inhibitors since December 2001. We believe that
this was an important factor that influenced the mutation patterns of HIV-1 protease and RT genes
in Thailand.
Background
During the last decade, the prevalence of human immun-
odeficiency virus type 1 (HIV-1) drug resistance has in-
creased in developed countries as a result of widespread
antiretroviral therapy [1–9]. Genotypic evidence of resist-
ance for any drug was found in fewer than 2% of cases in
one study from 1989 [4], increased to 10%-16% in co-
horts recruited after 1995 [2,3], and attained between
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20% and 26% in studies performed since 1997 [5–9].
Overall, several studies show rates of primary genotypic
drug resistance between 10% and 18% for nucleoside re-
verse transcriptase inhibitors (NRTIs), of none to 13% for
non-nucleoside reverse transcriptase inhibitors (NNRTIs),
and of 3% to 7% for protease inhibitors (PIs) [1–9].
In July 2002, S Sirivichayakul, et al. [10] reported genotyp-
ic resistant mutations of HIV-1 reverse transcriptase (RT)
in HIV-1 infected Thai patients who had been treated with
double nucleoside reverse transcriptase inhibitors
(NRTIs) for more than eight years. They found 54 (55.7%)
out of 97 patients failed to achieve viral suppression. The
genotypic analysis of HIV-1 RT isolated from these 54 pa-
tients showed that 61% and 18% of them had RT gene
mutations related to azidovudine (AZT) and lamivudine
(3TC) resistance, respectively. Mutations in the RT gene
related to other NRTI and multi-NRTI resistance were
found in low levels (1% to 4%). Interestingly, these pa-
tients' sequences also included NNRTI mutation (G190A)
without evidence of exposure to this drug class. In addi-
tion, no PI resistant mutations were reported. However,
the genotypic data showed in this report represents the re-
sistance information of only one ARV class (NRTIs). YK
Cho, et al. (2002) [11] reported the prevalence of HIV-1
drug resistance in South Korea where the AIDS epidemic
started at almost the same time that it started in Thailand.
They found that the viruses from 80% of NRTI-experi-
enced patients had mutations related to AZT resistance
while mutations related to 3TC and didanosine (ddI) re-
sistance were found in 11% and 5% of the patients, re-
spectively. In addition, no Q151M and NNRTI resistance-
related mutations were found.
There are approximately 1 million people infected with
HIV-1 in Thailand with 30,000 new infections every year
and 4,200 among children [12]. Only a few patients can
afford ARV drugs due to the high monthly price of effec-
tive treatment regimens. In addition, it is estimated that
only 5% of HIV-infected people can get access to ARV
double therapy and a very small number can get treatment
with three drugs [13].
On December 1, 2001, the Thai Government Pharmaceu-
tical Organization (GPO) reduced the monthly cost of
their ARV medications from 5,000 Baht (US$112) to
2,500 Baht (US$ 55). This has helped many infected peo-
ple (especially, low-income people) to improve their im-
mune status and control the virus load. However, it is
expected that the increased availability of the drugs may
change the drug resistance mutation pattern of HIV-1
among infected people in Thailand. To date, the frequen-
cy of ARV drug resistance in Thailand has not been well
characterized. So far, only one report concerning the fre-
quencies of both PI and RT inhibitor resistance mutations
in Thai patients has been found [14]. Therefore, this
study, which aims to investigate the prevalence and pat-
terns of HIV-1 genotypic resistance among antiretroviral-
treated Thai patients in 2002, may provide valuable infor-
mation that could guide the modification of regimen and
treatment strategies.
Methods
Study subjects
To investigate the prevalence of primary and secondary
drug-resistant viral genotypes circulating in Thailand, mu-
tations critical to the HIV-1 protease and reverse tran-
scriptase sequences were examined in plasma samples
collected from patients living in four large cities. Eighty-
eight samples (from 88 patients) were obtained from four
hospital centers, which are located in four regions of Thai-
land: Central (Bangkok; 56 samples), Northern (Chiang
Mai; 12 samples), Northeastern (Khon Kaen; 10 samples),
and Eastern (Chonburi; 10 samples). All plasma samples
were collected during 2002 from individuals living per-
manently in Thailand, who have been treated extensively
by ARV drug regimens and have failed to respond to treat-
ment (current plasma viral load of over 500 HIV-1 RNA
copies/ml). They were treated to all three classes of ARV
drugs (NRTIs, NNRTIs, and PIs) and were receiving a com-
bination of at least 2 classes of ARV drugs while the plas-
ma samples were collected. Samples from individuals on
drug holidays for longer than 2 weeks before the time of
the study were excluded because of the possibility of the
reversion of circulating mutant genotypes [15,16].
Genotyping
Viral RNA was isolated from plasma samples, using the
QIAamp viral extraction kit (Qiagen, Inc., Chatsworth,
CA, USA). The TRUGENE HIV-1 Genotyping Assay was
used in conjunction with the Open Gene automated DNA
sequencing system (Visible Genetics Inc., Toronto, Cana-
da) to sequence the protease and reverse transcriptase
(RT) regions of the HIV-1 cDNA. Testing involved simul-
taneous clip sequencing of protease and codons 35–244
of the RT from the amplified cDNA in both the 3' and 5'
directions. Sequences were aligned and compared with a
lymphoadenopathy-associated virus type 1 (HIV-B-LAV1)
consensus sequence using Visible Genetics Gene Librarian
software. We focused on mutation at positions in the
polymerase gene known to be associated with the com-
monly used drugs against HIV-1. Interpretation of the
genotype in terms of drug resistance was based on an al-
gorithm established by the Stanford HIV RT and Protease
Sequence Database http://hivdb.stanford.edu/hiv/[17].
The frequencies of resistant mutations were also com-
pared with the frequencies among Thai patients reported
by our group in 2001 [18]. DNA sequences generated in
this study have been submitted to GenBank under the ac-
cession numbers AF457212-AF457387.Annals of Clinical Microbiology and Antimicrobials 2003, 2 http://www.ann-clinmicrob.com/content/2/1/4
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Table 1: Frequency of mutations associated with resistance to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) in Thai patients in 2002.
Mutation(s) Frequency (%)
PIs 12
NRTIs 48
NNRTIs 21
All three drug families 12
Table 2: Distribution of resistant mutations in the reverse transcriptase and protease genes among the HIV-1 infected patients in 2001 
(83 patients) and 2002 (88 patients).
Mutations Patients, no. (%)
2001 2002
Mutations to NRTIs
M41L 28 38
E44D 0 9
A62V 2 3
K65R 2 3
D67N 38 40
T69D 5 6
K70R 25 23
L74V 2 6
V75M/T 0 15
F77L 0 4
F116Y 0 4
V118I 0 22
Q151M 3 3
V179D 2 3
M184V/I 46 27
H208Y 0 6
L210W 19 24
T215Y/F 36 45
K219Q 23 16
Mutations to NNRTIs
A98G 2 5
L100I 0 3
K101E 4 5
K103N 1 12
V108I 0 6
Y181C 4 8
G190A/S 7 12
Mutations to PIs
L10I/V 64 18
K20R 11 12
M36I 88 70
M46I 8 3
G48V 10 3
F53L 6 4
I54V 11 6
L63P 36 20
A71T/V 10 4
V82A/F 13 8
L90M 19 7Annals of Clinical Microbiology and Antimicrobials 2003, 2 http://www.ann-clinmicrob.com/content/2/1/4
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Results and Discussion
Sequence analysis of protease and RT regions
The details of patients' current ARV regimen are not
shown in this report, since only 30% of this data was well
recorded. Thus, in this report, we show only the frequen-
cies of resistant mutations of HIV-1 isolated from ARV-
treated Thai patients, and compare them with the frequen-
cies that were determined in 2001.
Genotypic resistance to protease inhibitor was noticed in
10 (12%) patients, whereas nucleoside reverse tran-
scriptase inhibitor and non-nucleoside reverse tran-
scriptase inhibitor key mutations were recognized in 42
(48%) and 19 (21%) patients, respectively (Table 1). The
most common resistant mutations among 88 subjects
were found at codons 82 (8%), 90 (7%) and 54 (6%)
within the protease gene and at codons 215 (45%), 67
(40%), 41 (38%) and 184 (27%) within the sequenced re-
gion of the RT gene. However, in contrast to the frequency
in 2001, the mutation at codon 75 of the RT gene was
found in up to 15% of the patients. Resistance to zidovu-
dine was mostly found (45%). The multi-nucleoside-re-
sistant genotype (Q151M) was found in three patients
while the insertion at codon 69 of RT gene was not found
in this study. Resistance to all three drug families (multi-
drug resistance) was recognized in 10 (12%) patients. Re-
sistance to NNRTIs in 2002 was much higher (21%) than
those found in 2001 (8%). As expected, changes at posi-
tions 103, 181 and 190 were the most frequently found
(Table 2). The results of our study also show that, in 2002,
the prevalence of mutations conferring PI resistance in
Thai patients was much lower (12%) than the prevalence
in 2001 (25%), whereas the mutations conferring NRTI
resistance stabilized at approximately 48%.
High prevalence of mutations conferring RT inhibitor re-
sistance noted in our study could be related to the reduc-
tion in the price of RT inhibitors in Thailand since
December 1, 2001. Moreover, in March 2002, the first
batch of 120,000 tablets of GPO-VIR (a combination of
nevirapine 200 mg, lamivudine 150 mg and stavudine 30
mg), produced by GPO, was made available at a cost of 20
Baht (US$ 0.46) a tablet. Reduced prices of the RT inhibi-
tors has led not only to an improvement in affordability
for patients but also increased the chance of RT inhibitor
resistant variants to become predominant in RT inhibitor
experienced patients. In addition, inadequate adherence
and the absence of monitoring the efficacy of the treat-
ment can rapidly lead to treatment failure as well as pro-
mote widespread of drug-resistant HIV strains. We believe
that the reduction of RT inhibitor cost was an important
factor that influenced the mutation patterns of HIV-1 pro-
tease and RT in 2002.
Bias concerning the sampling issues could explain the
lower rate of resistant mutations in protease and the high-
er rate of mutations conferring NNRTI resistance in this
study. However, the frequencies of resistant mutations re-
ported in 2001 and 2002 were from the same group and
the criteria for selecting patients and the geographic re-
gions within Thailand from where the patients were re-
cruited did not change. Therefore, no sampling bias is
apparent.
Conclusions
The frequencies of HIV-1 drug resistance mutations
among treated patients have changed after the reduction
in the price of RT inhibitor in Thailand since December
2001. The mutations related to RT inhibitor resistance
were found with high frequency, while the frequency of
mutations related to PI resistance was low. The patterns of
drug resistance mutations constantly change due to the
wide use of ARV drug therapy. Thus, one should be con-
cerned that the widespread of HIV-1 drug resistance
strains might seriously limit treatment options in the near
future.
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